AquaBounty Announced a Pause to Ohio Farm Construction While It Evaluated Alternatives
On Jun. 22, 2023 AquaBounty Technologies announced that the Company will pause the construction of its farm in…
AI system generated novel proteins that meet structural design targets
On Apr. 20, 2023, Massachusetts Institute of Technology (MIT) researchers announced that have developed machine-learning algorithms that can…
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | NIH | Therapeutics | Vaccine
Frequent testing reduced COVID-19 deaths in nursing facilities
On Apr. 4, 2023, National Institutes of Health (NIH) funded research was announced from the University of Rochester…
Moderna finalized agreement with Government of the Republic of Kenya to establish an mRNA manufacturing facility
On Mar. 30, 2023, Moderna and the Government of the Republic of Kenya announced they had finalized an…
Vaccine makers prep bird flu shot for humans ‘just in case’; rich nations lock in supplies
On Mar. 20, 2023, some of the world’s leading makers of flu vaccines said they could make hundreds…
Moderna to make milestone payments to NIH for COVID vaccine
On Feb. 24, 2023, Moderna announced will make certain contingent development, commercial and regulatory milestone payments to the…
Health Canada authorized Moderna’s Omicron-targeting bivalent COVID-19 vaccine in children & Adolescents
On Feb. 17, 2023, Moderna announced that Health Canada had authorized the use of its Omicron-targeting bivalent COVID-19…
Moderna to provide free COVID-19 vaccines after U.S. public health emergency ends
On Feb. 15, 2023, Moderna announced it will continue to offer its COVID-19 vaccines for free, even after…
Moderna announced mRNA-1345, an investigational RSV Vaccine, met primary efficacy endpoints in phase 3 trial
On Jan. 17, 2023, Moderna announced positive topline data from its ConquerRSV Phase 3 pivotal efficacy trial of…
Moderna finalized strategic partnership with UK government
On Dec. 21, 2022, Moderna announced the the finalization of a strategic partnership with the United Kingdom (UK)…
EMA Committee for Medicinal Products for Human Use rcommended use of Moderna’s BA.1 bivalent COVID-19 booster in children in the EU
On Dec. 16, 2022, Moderna announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use…
Moderna received FDA EUA for Omicron-targeting bivalent COVID-19 booster vaccine in children 6 months through 5 years of age
On Dec. 8, 2022, Moderna announced it had received emergency use authorization from the U.S. Food and Drug…
Moderna’s BA.4/BA.5 targeting bivalent booster, mRNA-1273.222, met primary endpoint of superiority against omicron variants
On Nov. 14, 2022, Moderna announced that both of Moderna’s bivalent Omicron-targeting booster candidates (mRNA-1273.214 and mRNA-1273.222) trigger…
Moderna received Health Canada authorization for second Omicron-targeting bivalent booster
On Nov. 4, 2022, Moderna announced that Health Canada had authorized the use of its BA.4/BA.5 Omicron-targeting bivalent…
Japan approved partial change to a NDA for Omicron-targeting bivalent booster COVID-19 vaccine
On Oct. 31, 2022, Moderna announced that it had received approval from the Ministry of Health, Labour and…
U.S. FDA recommended Novavax COVID-19 vaccine, adjuvanted as a booster in adults
On Oct. 19, 2022, the U.S. Food and Drug Administration (FDA) recommended the use of the Novavax COVID-19…
EMA’s CHMP for Human Use issued positive opinion recommending authorization for use of Spikevax in children 6 months – 5 years in EU
On Oct. 19, 2022, Moderna announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human…
90-Day analysis showed Moderna’s Omicron BA.1-targeting bivalent vaccine, mRNA-1273.214, demonstrated superior antibody response
On Oct. 19, 2022, Moderna announced new clinical data on its bivalent Omicron-containing booster, mRNA-1273.214. Ninety days after…
Moderna announced supply agreement with Gavi that secured access to updated variant-specific COVID-19 vaccines for low-and-middle income countries
On Oct. 17, 2022, Moderna and Gavi, the Vaccine Alliance, announced they had mutually agreed to cancel remaining…
Moderna received Authorization for Emergency Use from FDA of Omicron-targeting bivalent COVID-19 booster vaccine for children
On Oct. 12, 2022, Moderna announced that it had received emergency use authorization from the U.S. Food and…
EMA accepted Moderna’s conditional Marketing Authorization filing for omicron BA.4/BA.5 targeting bivalent COVID-19 vaccine
On Sept. 28, 2022, Moderna announced that the European Medicines Agency (EMA) had accepted a variation for the…
Moderna announced supplying 12 million doses of Omicron-containing bivalent COVID-19 booster vaccines to Government of Canada
On Aug. 23, 2022, Moderna announced that the Government of Canada had exercised its option to purchase an…
Medicines and Healthcare Products Regulatory Agency authorized Moderna’s Omicron-containing bivalent booster in the UK
On Aug. 15, 2022, Moderna announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK…
Moderna’s Omicron-containing bivalent booster candidate, mRNA-1273.214, demonstrated higher neutralizing antibody response
On Aug. 9, 2022, Moderna announced an amendment to its agreement with the European Commission (EC) to convert…
HHS announced 66 million doses of Moderna’s variant-specific COVID-19 vaccine booster for potential use in Fall and Winter 2022
On Jul. 29, 2022, the U.S. Department of Health and Human Services (HHS), in collaboration with the U.S….
EMA Committee for Medicinal Products for Human Use recommended use of the Moderna COVID-19 booster in adolescents (12-17 years)
On Jul. 22, 2022, Moderna announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human…
Australia TGA granted provisional approval for Moderna’s COVID-19 vaccine in children aged six months to five years
On Jul. 18, 2022, Moderna announced that the Therapeutic Goods Administration (TGA) in Australia had granted provisional registration…
Health Canada authorized Moderna’s COVID-19 vaccine in young children (6 months-5 years)
On Jul. 14, 2022, Moderna announced that Health Canada had approved the use of Moderna’s mRNA COVID-19 vaccine,…
NIH launched clinical trial of mRNA Nipah virus vaccine
On Jul. 11, 2022, the National Institute of Allergy and Infectious Diseases (NIAID) launched an early-stage clinical trial…
Moderna received FDA authorization for EUA of Its COVID-19 vaccine for children 6 months of age and older
On Jun. 17, 2022, Moderna announced that it had received emergency use authorization from the U.S. Food and…